Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany.
Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Contrast Media Mol Imaging. 2019 Jan 3;2019:6438196. doi: 10.1155/2019/6438196. eCollection 2019.
Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of Lu-OPS201 in animals and humans.
Data on biokinetics of Lu-OPS201 were analyzed in athymic nude mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19-0.27 MBq (mice), 97-113 MBq (pigs), and 850-1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared.
A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs' kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h).
If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics.
Lu-OPS201 是一种用于神经内分泌肿瘤 PRRT 的高亲和力生长抑素受体亚型 2 拮抗剂。目的是找到最佳的剂量测定标度,并比较 Lu-OPS201 在动物和人体中的生物动力学。
对在无胸腺裸鼠(28 只 F,体重:26 ± 1g)、丹麦长白猪(3 只 F-1 只 M,体重:28 ± 2kg)和患者(3 只 F-1 只 M,体重:61 ± 17kg)中 Lu-OPS201 的生物动力学数据进行分析,给予的活动度分别为 0.19-0.27MBq(小鼠)、97-113MBq(猪)和 850-1086MBq(患者)。在处死小鼠(最长 168 小时)后,测量器官特异性活度含量(包括血液)。进行多次平面和 SPECT/CT 扫描,直到 250 小时(猪)和 72 小时(患者),以量化肾脏和肝脏的摄取情况。患者最多采集 23 小时的血液样本,猪则采集 300 小时的血液样本。对猪和患者进行了肾脏保护。为每个物种和器官/组织创建了时间依赖性摄取数据集。对每个物种的肾脏、肝脏和血液中的生物动力学进行双指数拟合。通过 NUKFIT 计算时间积分活度系数(TIAC)。为了确定最佳标度,比较了几种方法(相对质量标度、时间标度、质量和时间组合标度以及比例标度)。
所有物种的化合物在第一阶段(<56 小时)均表现出快速的血液清除。与患者相比,猪的肝脏保留率更高。基于 TIAC 的直接比较,与患者数据相比,小鼠(肾脏和肝脏)和猪的肾脏(肾脏 TIAC:小鼠=1.4 小时,猪=7.7 小时,患者=5.8 小时;肝脏 TIAC:小鼠=0.7 小时,猪=4.1 小时,患者=5.3 小时)存在低估,而猪的肾脏存在高估。通过应用时间标度(小鼠)和组合标度(猪),获得了最相似的 TIAC(肾脏 TIAC:小鼠=3.9 小时,猪=4.8 小时,患者=5.8 小时;肝脏 TIAC:小鼠=0.9 小时,猪=4.7 小时,患者=5.3 小时)。
如果物种间的器官质量比很高,则组合质量和时间标度方法是最小化种间差异的最佳方法。拟合函数和 TIAC 的分析表明,猪更能模拟人体的生物动力学。